RNA and Protein Degrader/Modulator Modalities of Small Molecules
In the evolving landscape of drug discovery, RNA and protein degrader/modulator modalities have emerged as revolutionary approaches in small-molecule therapeutics. These cutting-edge strategies offer a pathway to tackle previously “undruggable” targets and expand therapeutic horizons across multiple disease areas.
At Aragen Life Sciences, we empower innovation in Integrated Drug Discovery (IDD) by advancing cutting-edge RNA and protein degrader/modulator platforms. Our expertise transforms challenging drug targets into therapeutic realities, enabling breakthroughs across oncology, CNS disorders, inflammation, metabolic diseases, and more.
RNA-Targeting Small Molecules
Small molecules targeting RNA are reshaping the therapeutic landscape by modulating gene expression at its source. These molecules can:
Applications span oncology, rare genetic disorders, metabolic diseases, and infectious diseases, offering precision intervention at the molecular level.
Comprehensive Support for Next-Generation Modalities
As a Contract Research Organization (CRO), we offer end-to-end support in RNA and protein degrader/modulator development, including:
Partner with us to pioneer transformative therapies in RNA and protein modulation. Let’s redefine the boundaries of small-molecule drug discovery together.
